Lymphoma Clinical Trials in Washington

Showing 261-280 of 304 trials

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

NCT00319332

This is a multi-center, randomized, study to compare Iodine I 131 Tositumomab therapeutic regimen to Ibritumomab Tiuxetan therapeutic regimen in the treatment of patients with relapsed or transformed follicular non-Hodgkin's B-cell lymphoma. A total of 350 patients, approximately 175 patients per arm, will be enrolled at 30 to 40 sites in the United States.

Lymphoma, Small Cleaved-Cell, FollicularLymphoma, Large-Cell, FollicularLymphoma, Follicular+1 more

GlaxoSmithKlineStarted Sep 2005

Iowa City, Iowa, United States • St Louis, Missouri, United States • Buffalo, New York, United States +5 more locations

COMPLETEDPhase 342 miles

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

NCT00117598

This is an open-label, randomized trial in relapsed refractory subjects with mantle cell lymphoma (MCL).

Lymphoma

Pfizer169 participantsStarted May 2005

Little Rock, Arkansas, United States • Fountain Valley, California, United States • Los Angeles, California, United States +70 more locations

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

Lymphoma Trials in Other Cities

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease

Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation

SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

Other Conditions in Washington